

**UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
OFFICE OF ADMINISTRATIVE LAW JUDGES**

_____))
In the Matter of))
))
Amgen Inc.,))
a corporation, and))
)) Docket No. 9414
Horizon Therapeutics PLC,))
a corporation,))
))
Respondents.))
_____)


**ORDER GRANTING RESPONDENTS’ UNOPPOSED MOTION
FOR AN ORDER TO ADDRESS DISCLOSURES
OF RESPONDENTS’ CONFIDENTIAL INFORMATION**

On July 5, 2023, pursuant to Rules 3.22(c) and (d) of the Federal Trade Commission (the “FTC”) Rules of Practice, 16 C.F.R. ¶ 3.22, Respondents Amgen Inc. (“Amgen”) and Horizon Therapeutics PLC (“Horizon”) filed a motion seeking an order to address the disclosures by FTC Complaint Counsel of certain confidential information produced by Respondents Amgen and Horizon to the FTC during the FTC’s investigation into Amgen’s proposed acquisition of Horizon (the “Confidential Information”). Respondents attach a letter from Complaint Counsel, dated June 28, 2023, stating that Complaint Counsel does not oppose Respondents’ motion. (Motion, Ex. A).

The unopposed motion is GRANTED.

IT IS ORDERED THAT Complaint Counsel shall (i) identify every person who may have improperly accessed Respondents’ Confidential Information that was disclosed by Complaint Counsel, and (ii) take all actions necessary to ensure that those persons destroy any improperly accessed Confidential Information and make no use of it in any way.

ORDERED:


D. Michael Chappell
Chief Administrative Law Judge

Date: July 7, 2023